Quanterix Corporation, a life sciences company, develops and markets ultra-sensitive digital immunoassay platform that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Simoa HD-1 instrument, a sensitive automated multiplex protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection technology in various applications, including direct detection of nucleic acids. It also develops SP-X instrument that is based on Simoa planar array technology for the measurement of multiplex chemiluminescent immunoassays. The company’s products include kits, such as beads, capture and detector reagents, enzyme reagents, and enzyme substrates to run tests; and consumables, such as proprietary Simoa disks, cuvettes, and disposable tips. In addition, it offers contract research services, including sample testing, homebrew assay development, and custom development services. The company primarily operates in the areas of neurology, oncology, cardiology, infectious diseases, and inflammation. It sell its products for the life science research sector primarily to laboratories associated with academic and governmental research institutions, as well as pharmaceutical, biotechnology, and contract research companies through a direct sales force, support organizations, and distributors or sales agents. The company was formerly known as Digital Genomics, Inc. and changed its name to Quanterix Corporation in August 2007. Quanterix Corporation was incorporated in 2007 and is headquartered in Billerica, Massachusetts.

  • Quanterix to Convene Leading Industry Researchers at Alzheimer’s Association International Conference 2019 Following Closing of UmanDiagnostics Acquisition
    on July 11, 2019 at 5:30 pm

    Quanterix Corporation (QTRX), a company digitizing biomarker analysis with the goal of advancing the science of precision health, marks the end of the first half of 2019 with major milestones as it continues to expand its footprint in neurology and lead the digital biomarker revolution across healthcare. Most recently, on July 1, Quanterix announced it had closed its acquisition of UmanDiagnostics AB, a company widely recognized as the leading provider of antibodies to measure Nf-L. “Quanterix has realized significant growth attributable to our new technological inovations and company expansions, but also from a growing consensus that biomarkers can transform healthcare,” said Kevin Hrusovsky, Chief Executive Officer, President and Chairman of Quanterix. […]

  • Quanterix Announces Kevin Hrusovsky, Chairman and Chief Executive Officer, and Founder of Powering Precision Health, as EY Entrepreneur Of The Year® 2019 Award Winner in New England
    on June 28, 2019 at 4:15 pm

    Quanterix Corporation (QTRX), a company digitizing biomarker analysis with the goal of advancing the science of precision health, today announced that Kevin Hrusovsky, Chairman and CEO of Quanterix, and Founder of Powering Precision Health (PPH), has been recognized with the Entrepreneur Of The Year® 2019 Award in the New England region by EY. The award acknowledges Hrusovsky’s achievements in healthcare technology innovation, Quanterix’ outstanding financial performance, and his personal commitment to improving precision health. “We are honored to be recognized by EY,” said Hrusovsky. […]

  • Mass. diagnostics firms sign M&A deals worth $500M
    on June 27, 2019 at 2:43 pm

    Two local diagnostics firms, one of which is working in the increasingly competitive field of cancer testing, closed acquisition deals this week worth around $500 million. […]

  • Quanterix Announces Agreement to Acquire UmanDiagnostics, World’s Leading Neurofilament Light (Nf-L) Antibody Supplier
    on June 26, 2019 at 8:00 pm

    Quanterix Corporation (QTRX), a company digitizing biomarker analysis with the goal of advancing the science of precision health, today announced that it has entered into a definitive agreement to acquire privately held UmanDiagnostics AB for $22.5 million, comprised of $16 million in cash plus $6.5 million in Quanterix common stock. Uman is widely recognized to possess the leading antibodies available today to measure neurofilament light (Nf-L) and has become the provider of choice for biopharmaceutical and diagnostic applications. […]

  • Did Quanterix's (NASDAQ:QTRX) Share Price Deserve to Gain 66%?
    on June 6, 2019 at 11:03 am

    If you want to compound wealth in the stock market, you can do so by buying an index fund. But if you pick the right... […]

  • Quanterix Raises $49.7 Million and Announces Introduction of Latest Model Simoa HD-X Analyzer at BIO 2019 International Convention
    on June 4, 2019 at 8:00 pm

    Quanterix Corporation (QTRX), a company digitizing biomarker analysis with the goal of advancing the science of precision health, announced that it issued approximately 2.2 million shares of common stock last week, raising $49.7 million in gross proceeds. Additionally, Quanterix will unveil its Simoa HD-X Analyzer™, at the BIO International Convention, in Philadelphia, during a presentation by its Chairman and CEO, Kevin Hrusovsky, taking place June 5 at 10:45 a.m., EDT, in Theater 3. Quanterix is re-engineering ultra-sensitivity with the launch of the HD-X, its latest fully automated Simoa bead-based immunoassay instrument model. […]

  • Quanterix Expands Headquarters to New, State-of-the-Art Facility in Billerica, Mass. as Demand Continues to Grow for its Disruptive Simoa Platforms
    on May 29, 2019 at 8:00 pm

    Quanterix Corporation (QTRX), a company digitizing biomarker analysis with the goal of advancing the science of precision health, today announced the relocation of its headquarters to a brand new, state-of-the-art facility in Billerica, Mass. Brought on by Quanterix’ rapid growth, the move will allow the Company to unite its CLIA-certified laboratory with its expanding workforce to accelerate entry into pharmaceutical drug services and further increase its impact on the transformation of precision healthcare. “We experienced considerable success in our former facilities, launching several new biomarker technologies that are beginning to disrupt drug development and drug approval methodologies, acquiring Aushon to accelerate our entry into Biopharma services and leading a successful public offering in December 2017,” said Kevin Hrusovsky, Chairman and CEO, Quanterix. […]

  • Quanterix Announces $50,000 in Grants to Support Promising Oncology Research
    on May 16, 2019 at 2:30 pm

    Quanterix Corporation (QTRX), a company digitizing biomarker analysis to advance the science of precision health, today announced a call for proposals for a new Accelerator Grant Program. Designed to help facilitate breakthroughs in science and medicine, this year’s Accelerator Grant Program will award up to $50,000 toward the cost of research in Quanterix’ Accelerator Lab to help advance the most exciting biomarker research using Quanterix’ ultrasensitive Simoa technology. […]

  • Here’s What Hedge Funds Think About Quanterix Corporation (QTRX)
    on May 11, 2019 at 5:27 pm

    The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data. We have processed the filings of the more than 700 world-class investment firms that we track and now have access to the collective wisdom contained in […]

  • Quanterix Corporation (QTRX) Q1 2019 Earnings Call Transcript
    on May 10, 2019 at 3:23 pm

    QTRX earnings call for the period ending March 31, 2019. […]

1 years ago


On Memorial Day we must keep in mind the importance of continued research to improve brain health. Early detection of traumatic brain injuries can significantly improve the way we treat the condition and provide more effective options for soldiers and veterans. ... See MoreSee Less

View on Facebook

We're still not over our @EY_EOYUS win! Check out this video from the gala that includes the team's heartfelt remarks on how our CEO @KevinHrusovsky’s #leadership + resolve to conquer #disease inspires them every day. #EOYNE #Entrepreneurship. https://t.co/NLRbK5S7MB

We had a special guest in the office today who received some #Buckeye luck from our CEO @KevinHrusovsky! Perhaps a young #healthcare innovator in the making? 🤔We sure hope so! #STEM #LifeatQuanterix

Our CEO @KevinHrusovsky recently sat down with @wstranscript to discuss our Simoa tech and how we’re helping everyone from #academia to #pharma disrupt #healthcare through early detection and improved #drugdevelopment. Learn more: https://t.co/7n9C1kzOP4

In the face of recent drug trial failures we must diversify and develop a better understanding of Alzheimer's disease @DrMariaALZ. Fantastic opening speech welcoming #AAIC19 attendees

We’re actively supporting #Alzheimers disease research to make progress with earlier diagnosis & #drugdevelopment. Come visit us at booth 526 at #AAIC19 to see how our tech is making a difference. #ENDALZ

This #MotivationMonday, we recognize @KevinHrusovsky! Check out this video to see how our @EY_EOYUS award-winning CEO inspires us each and every day! #leadership #companyculture #LifeatQuanterix https://t.co/NLRbK5S7MB

Our efforts to #ENDALZ will be in full force at #AAIC19. We are convening top minds from @UniBasel, @uniofgothenburg, @UCSanDiego & more to discuss the future of detection and treatment. Visit us at booth 526 https://t.co/u6OpQsAVGv

The latest issue of IBO is out! It features IBO's annual Productivity Review, as well as coverage on @QuanterixSimoa's recent M&A, @illumina's legal actions toward @BGI_Genomics, and much more! Click here to access: https://t.co/HQXsqfB8Bs

We're uniting our unparalleled #biomarker detection tech with UmanDiagnostics' world-leading neurofilament light #antibodies to double down on the fight against lethal #neurology disorders. More on our big news here: https://t.co/QWGJJqn2Th #acquisition #biotech

Load More...

    Feed has no items.

    Feed has no items.


What's Your Role?*



Company Description*



Quanterix Corporation

Building 1
900 Middlesex Turnpike
Billerica, MA 01821

+1 (617) 301-9400


July 2019
« Apr    

©2019 ALIGNMT LLC | Alignment Consulting | Mergers & Acquisitions | Investor Relations


We're not around right now. But you can send us an email and we'll get back to you, asap.


Log in with your credentials


Forgot your details?

Create Account